top
Search terms
Results 1 - 10 of 12 - ordered by :
Pages: 1 2
Epeuropace

Abstract Aim Differential drug treatment guided by the underlying heart disease may improve outcome of rhythm control therapy. In the present study we investigated in a well-defined group with ...

Europace, Regular Article, Trudeke Van Noord, Robert G. Tieleman, Hans A. Bosker, Tsjerk Kingma, Dirk J. Van Veldhuisen, Harry J.G.M Crijns, Isabelle C. Van Gelder

Date : 01/01/2004 Item size : 226294 bytes
Epeuropace

Myocardial perfusion imaging does not adequately assess the risk of coronary artery disease in patients with atrial fibrillation Abstract Aims The role of coronary artery disease (CAD) in atrial ...

Europace, Atrial Fibrillation - Clinical Issues, Marcelle D. Smit, René A. Tio, Riemer H.J.A. Slart, Felix Zijlstra, Isabelle C. Van Gelder

Date : 01/05/2010 Item size : 217053 bytes
Ehjcardiovascrec

Introduction Atrial fibrillation (AF) is the most common cardiac arrhythmia, having a prevalence of 1% in young patients up to 9% in patients at the age of 75 years.1 It is estimated that the ...

Cardiovascular Research, REVIEWS: FOCUS ON THE MOLECULAR BASIS OF ATRIAL FIBRILLATION, Anne Margreet De Jong, Alexander H. Maass, Silke U. Oberdorf-Maass, Dirk J. Van Veldhuisen, Wiek H. Van Gilst, ...

Date : 01/03/2011 Item size : 631934 bytes
Epeuropace

GuidelinesAtrial fibrillationAnticoagulationVitamin K antagonistsNon-vitamin K antagonist oral anticoagulantsLeft atrial appendage occlusionRate controlCardioversionRhythm controlAntiarrhythmic ...

Europace, ESC Guidelines, Paulus Kirchhof, Stefano Benussi, Dipak Kotecha, Anders Ahlsson, Dan Atar, Barbara Casadei, Manuel Castella, Hans-Christoph Diener, Hein Heidbuchel, Jeroen Hendriks, Gerhard ...

Date : 01/11/2016
Epeuropace

Episodic Prophylactic Treatment with Amiodarone for the Prevention of AF (CONVERT) study, using the Short Form (SF)-36 health survey and University of Toronto AF Severity Scale (AF severity scale) ...

Europace, Atrial Fibrillation - Clinical Issues, Sheba Ahmed, Adelita V. Ranchor, Harry J.G.M. Crijns, Dirk J. Van Veldhuisen, Isabelle C. Van Gelder, for the CONVERT investigators

Date : 01/06/2010
Epeuropace

[...]in the present neurohormonal substudy of PRIME II only patients with systolic left ventricular dysfunction were included. The final model of determinants of BNP consisted of left ventricular ...

Europace, Letter to the Editor, Michiel Rienstra, Isabelle C. Van Gelder, Maarten P. Van den Berg, Dirk J. Van Veldhuisen

Date : 01/02/2007
Epeuropace

Outcome of pharmacological rhythm control for new-onset persistent atrial fibrillation in patients with systolic heart failure: a comparison with patients with normal left ventricular ...

Europace, ANTIARRHYTHMIC DRUGS, Martin E.W. Hemels, Ans C.P. Wiesfeld, Dirk J. Van Veldhuisen, Maarten P. Van den Berg, Isabelle C. Van Gelder

Date : 01/04/2007
Epeuropace

Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP Abstract Aims To study the determinants of ...

Europace, FOCUS ON ATRIAL ARRHYTHMIAS, Michiel Rienstra, Isabelle C. Van Gelder, Maarten P. Van den Berg, Frans Boomsma, Dirk J. Van Veldhuisen

Date : 01/07/2006
Epeuropace

Results Centre characteristics Responses were received from 57 centres participating in the EHRA EP research network over a wide geographical area. Activity, equipment, and technique of ...

Europace, EP WIRE, Antonio Hernández-Madrid, Jesper Hastrup Svendsen, Gregory Y.H. Lip, Isabelle C. Van Gelder, Dan Dobreanu, Carina Blomstrom-Lundqvist, conducted by the Scientific Initiatives ...

Date : 01/06/2013
Epeuropace

Clinical trials comparing rate control with rhythm control Randomized trials comparing outcomes of rhythm vs. rate control strategies in patients with AF are summarized in Tables 13 and 14.8692 Among ...

Europace, ESC GUIDELINES, Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), ...

Date : 01/10/2010